None declared.
Abstract A billion deaths from tobacco are expected by 2100. Many policy interventions such as increased taxation, restrictions on advertisement, smoking bans, as well as behavioral interventions, such as pharmacological and psychological treatments for smoking cessation, decrease tobacco use, but they reach their limits. Endgame scenarios focusing on tobacco supply rather than demand are increasingly discussed, but meet with resistance by the industry and even by many tobacco control experts. A main stumbling block that requires more attention is what to do with the tobacco industry in endgame scenarios. This industry has employed notoriously talented experts in law, business, organization, marketing, advertising, strategy, policy, and statistics and has tremendous lobbying power. Performance‐based regulatory approaches can pose a legal obligation on manufacturers to decrease – and eventually – eliminate tobacco products according to specified schedules. Penalties and rewards can make such plans both beneficial for public health and attractive to the companies that do the job well. We discuss caveats and reality checks of engaging the tobacco industry to eliminate its current market and change focus. Brainstorming is warranted to entice the industry to abandon tobacco for other profit goals. To get the dialogue started, we propose the wild possibility of hiring former tobacco companies to reduce the costs of healthcare, thereby addressing concurrently two major challenges to public health.
The ability of a camera to record a high dynamic range image, whether by taking one snapshot or a sequence, is limited by the presence of veiling glare - the tendency of bright objects in the scene to reduce the contrast everywhere within the field of view. Veiling glare is a global illumination effect that arises from multiple scattering of light inside the camera's body and lens optics. By measuring separately the direct and indirect components of the intra-camera light transport, one can increase the maximum dynamic range a particular camera is capable of recording. In this paper, we quantify the presence of veiling glare and related optical artifacts for several types of digital cameras, and we describe two methods for removing them: deconvolution by a measured glare spread function, and a novel direct-indirect separation of the lens transport using a structured occlusion mask. In the second method, we selectively block the light that contributes to veiling glare, thereby attaining significantly higher signal-to-noise ratios than with deconvolution. Finally, we demonstrate our separation method for several combinations of cameras and realistic scenes.
Many animals rely on visual motion detection for survival. Motion information is extracted from spatiotemporal intensity patterns on the retina, a paradigmatic neural computation. A phenomenological model, the Hassenstein-Reichardt correlator (HRC), relates visual inputs to neural activity and behavioral responses to motion, but the circuits that implement this computation remain unknown. By using cell-type specific genetic silencing, minimal motion stimuli, and in vivo calcium imaging, we examine two critical HRC inputs. These two pathways respond preferentially to light and dark moving edges. We demonstrate that these pathways perform overlapping but complementary subsets of the computations underlying the HRC. A numerical model implementing differential weighting of these operations displays the observed edge preferences. Intriguingly, these pathways are distinguished by their sensitivities to a stimulus correlation that corresponds to an illusory percept, “reverse phi,” that affects many species. Thus, this computational architecture may be widely used to achieve edge selectivity in motion detection.
This paper describes IRSIM, an incremental switch-level simulator for MOS transistor circuits. In IRSIM, the circuit under simulation can be modified and then incrementally resimulated. This allows error correction and circuit operation verification to be performed in time proportional to the size of the modifications rather than the size of the entire circuit. To accomplish this incremental simulation, IRSIM maintains a history of circuit activity during simulation and only resimulates the sections of the circuit that deviate from their history. The program was tested on several corrections to errors that actually occurred in the design of a VLSI microprocessor. These errors were corrected and the circuit was incrementally resimulated 1.6 to 3500 times faster than simulating the entire circuit.
Abstract STUDY QUESTION What were the frequency and temporal trends of reporting P-values and effect measures in the abstracts of reproductive medicine studies in 1990–2022, how were reported P-values distributed, and what proportion of articles that present with statistical inference reported statistically significant results, i.e. ‘positive’ results? SUMMARY ANSWER Around one in six abstracts reported P-values alone without effect measures, while the prevalence of effect measures, whether reported alone or accompanied by P-values, has been increasing, especially in meta-analyses and randomized controlled trials (RCTs); the reported P-values were frequently observed around certain cut-off values, notably at 0.001, 0.01, or 0.05, and among abstracts present with statistical inference (i.e. P-value, CIs, or significant terms), a large majority (77%) reported at least one statistically significant finding. WHAT IS KNOWN ALREADY Publishing or reporting only results that show a ‘positive’ finding causes bias in evaluating interventions and risk factors and may incur adverse health outcomes for patients. Despite efforts to minimize publication reporting bias in medical research, it remains unclear whether the magnitude and patterns of the bias have changed over time. STUDY DESIGN, SIZE, DURATION We studied abstracts of reproductive medicine studies from 1990 to 2022. The reproductive medicine studies were published in 23 first-quartile journals under the category of Obstetrics and Gynaecology and Reproductive Biology in Journal Citation Reports and 5 high-impact general medical journals (The Journal of the American Medical Association, The Lancet, The BMJ, The New England Journal of Medicine, and PLoS Medicine). Articles without abstracts, animal studies, and non-research articles, such as case reports or guidelines, were excluded. PARTICIPANTS/MATERIALS, SETTING, METHODS Automated text-mining was used to extract three types of statistical significance reporting, including P-values, CIs, and text description. Meanwhile, abstracts were text-mined for the presence of effect size metrics and Bayes factors. Five hundred abstracts were randomly selected and manually checked for the accuracy of automatic text extraction. The extracted statistical significance information was then analysed for temporal trends and distribution in general as well as in subgroups of study designs and journals. MAIN RESULTS AND THE ROLE OF CHANCE A total of 24 907 eligible reproductive medicine articles were identified from 170 739 screened articles published in 28 journals. The proportion of abstracts not reporting any statistical significance inference halved from 81% (95% CI, 76–84%) in 1990 to 40% (95% CI, 38–44%) in 2021, while reporting P-values alone remained relatively stable, at 15% (95% CI, 12–18%) in 1990 and 19% (95% CI, 16–22%) in 2021. By contrast, the proportion of abstracts reporting effect measures alone increased considerably from 4.1% (95% CI, 2.6–6.3%) in 1990 to 26% (95% CI, 23–29%) in 2021. Similarly, the proportion of abstracts reporting effect measures together with P-values showed substantial growth from 0.8% (95% CI, 0.3–2.2%) to 14% (95% CI, 12–17%) during the same timeframe. Of 30 182 statistical significance inferences, 56% (n = 17 077) conveyed statistical inferences via P-values alone, 30% (n = 8945) via text description alone such as significant or non-significant, 9.3% (n = 2820) via CIs alone, and 4.7% (n = 1340) via both CI and P-values. The reported P-values (n = 18 417), including both a continuum of P-values and dichotomized P-values, were frequently observed around common cut-off values such as 0.001 (20%), 0.05 (16%), and 0.01 (10%). Of the 13 200 reproductive medicine abstracts containing at least one statistical inference, 77% of abstracts made at least one statistically significant statement. Among articles that reported statistical inference, a decline in the proportion of making at least one statistically significant inference was only seen in RCTs, dropping from 71% (95% CI, 48–88%) in 1990 to 59% (95% CI, 42–73%) in 2021, whereas the proportion in the rest of study types remained almost constant over the years. Of abstracts that reported P-value, 87% (95% CI, 86–88%) reported at least one statistically significant P-value; it was 92% (95% CI, 82–97%) in 1990 and reached its peak at 97% (95% CI, 93–99%) in 2001 before declining to 81% (95% CI, 76–85%) in 2021. LIMITATIONS, REASONS FOR CAUTION First, our analysis focused solely on reporting patterns in abstracts but not full-text papers; however, in principle, abstracts should include condensed impartial information and avoid selective reporting. Second, while we attempted to identify all types of statistical significance reporting, our text mining was not flawless. However, the manual assessment showed that inaccuracies were not frequent. WIDER IMPLICATIONS OF THE FINDINGS There is a welcome trend that effect measures are increasingly reported in the abstracts of reproductive medicine studies, specifically in RCTs and meta-analyses. Publication reporting bias remains a major concern. Inflated estimates of interventions and risk factors could harm decisions built upon biased evidence, including clinical recommendations and planning of future research. STUDY FUNDING/COMPETING INTEREST(S) No funding was received for this study. B.W.M. is supported by an NHMRC Investigator grant (GNT1176437); B.W.M. reports research grants and travel support from Merck and consultancy from Merch and ObsEva. W.L. is supported by an NHMRC Investigator Grant (GNT2016729). Q.F. reports receiving a PhD scholarship from Merck. The other author has no conflict of interest to declare. TRIAL REGISTRATION NUMBER N/A.
pSS is associated with sensorineural hearing loss affecting preferentially the high frequencies, but clinically significant defects are not common. There is no evidence of retrocochlear disease or increased vestibular involvement in pSS.
